ClinicalTrials.gg
CompletedNCT03122730Updated Jul 31, 2025Results posted

VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB

A Phase 2 interventional study of VentaProst in Pulmonary Hypertension, sponsored by Aerogen Pharma Limited. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Aerogen Pharma Limited · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 397 studies in Hypertension, Pulmonary with a site in United States — 72 open to participants now, 86 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.

Enrollment
186th of 286
17 · median 30
Started
2017
with 19 others
Phase 2
93 of 397
13 open now
Registered
241st of 397
by date

Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 186th largest by enrollment of the 286 interventional ones that give a count, is one of 20 that started in 2017, is one of 93 in phase 2, and was the 241st registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

72 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 397 studies in Hypertension, Pulmonary with a site in United States, or all of them as a file.
02

Study summary

The purpose of the Phase 2a study is to: 1) demonstrate that the estimated VentaProst dose is safe and equivalent in effect to a dose administered via epoprostenol aerosolization by the current off-label-use practice; and 2) demonstrate that an optimum effect can be rapidly obtained with VentaProst titration.

Read the detailed description

Part I:

This part of the study is designed to demonstrate the dose equivalence between off-label aerosolized epoprostenol and VentaProst using a patient's hemodynamic parameters.

Part II:

This part of the study is designed to establish a dose response relationship of VentaProst to hemodynamic effect by dose escalation in patients who have had cardiac surgery with CPB.

03

Conditions studied

  • Pulmonary Hypertension

Keywords

  • Cardiac surgery
  • Cardiopulmonary bypass
  • Epoprostenol
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women and Men 18 to 75 years of age
  2. Provide written
  3. Willing and able to comply with all aspects of the protocol
  4. For patients in Part I:

    1. Undergo cardiac surgery on CPB
    2. Clinically require treatment with and receive aerosolized epoprostenol
    3. Demonstrate a hemodynamic response to aerosolized epoprostenol
  5. For patients in Part II:

    1. Undergo cardiac surgery with CPB
    2. Have perioperative pulmonary hypertension
    3. Clinically require treatment with inhaled epoprostenol

Exclusion criteria

Exclusion Criteria:

  1. Current smoker (i.e., within the last 30 days)
  2. Emergency operative status
  3. Upper and/or lower respiratory tract infection within four weeks of screening
  4. to transesophageal echocardiogram (TEE) including esophageal disease or unstable cervical spine
  5. Renal or severe hepatic impairment
  6. Thromboembolic disease treated with anticoagulant therapy
  7. Bleeding disorders
  8. Significant restrictive or obstructive lung disease
  9. History of concurrent or recurrence of malignancy within two years prior to Screening
  10. History of a diagnosis of drug or alcohol dependency or abuse within approximately the last three years
  11. Recent history of stroke or
  12. Significantly abnormal laboratory tests at Screening
  13. Pregnant or breastfeeding
  14. Treatment with an drug, biologic, or device within 30 days
  15. Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the Investigator or Sponsor, would make the patient inappropriate for entry into this trial
  16. Any condition where aerosolized epoprostenol is contraindicated
  17. Known allergy or sensitivity to epoprostenol, any of its ingredients, or the diluent
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    VentaProst

    VentaProst (epoprostenol solution for inhalation via custom drug delivery system) In Part 1, subjects were treated with a commercial aerosolized epoprostenol and then removed from that treatment. VentaProst was started and titrated to a dose equivalence to maintain at least 90% of hemodynamic response seen with the commerical product. In Part 2, subjects were treated with VentaProst only.

    Combination Product: VentaProst

Interventions

  • Combination productVentaProst

    epoprostenol for inhalation via custom drug delivery system

06

What researchers measure

Primary outcomes

  1. Identify Equivalent Dose of VentaProst Necessary to Achieve a PD Response Comparable to Standard of Care Treatment (Part I)

    The primary goal was to establish the dose of VentaProst necessary to achieve a PD response comparable to the standard of care. The first dose of VentaProst tested, 17 ng/kg/min, achieved the dose equivalency.

    Time frame: Pharmacodynamic changes will be measured during surgery (Day 1), post-surgery (Day 1), and from start of study treatment (Day 1) through study completion (up to 30 days)

Secondary outcomes

  1. Optimal Dose Determination With VP Dose Escalation (Part II)

    Calculate vascular resistance indicators for CI and CO, and PAPi at each dose level. Identify the VP dose where mPAP, VR(CO), VR(CI), CVP are lowest, and CI/CO are highest. Compare in a narrative to the selected VP optimal dose by the Investigator by individual patient.

    Time frame: Pharmacodynamic changes will be measured during surgery (Day 1), post-surgery (Day 1), and from start of study treatment (Day 1) through study completion (up to 30 days)

07

Results

Posted Jul 31, 2025

Participant flow

Part 1: Epoprostenol Then VentaProst
Participant flow — Part 1: Epoprostenol Then VentaProst
MilestoneVentaProst
Started9
Completed7
Not completed2
Part 2: VentaProst Dose Escalation
Participant flow — Part 2: VentaProst Dose Escalation
MilestoneVentaProst
Started8
Completed8
Not completed0

Outcome measures

PrimaryIdentify Equivalent Dose of VentaProst Necessary to Achieve a PD Response Comparable to Standard of Care Treatment (Part I)

The primary goal was to establish the dose of VentaProst necessary to achieve a PD response comparable to the standard of care. The first dose of VentaProst tested, 17 ng/kg/min, achieved the dose equivalency.

Time frame:
Pharmacodynamic changes will be measured during surgery (Day 1), post-surgery (Day 1), and from start of study treatment (Day 1) through study completion (up to 30 days)
Reported as:
Number · ng/kg/min
Identify Equivalent Dose of VentaProst Necessary to Achieve a PD Response Comparable to Standard of Care Treatment (Part I)
ng/kg/minVentaProst
Identify Equivalent Dose of VentaProst Necessary to Achieve a PD Response Comparable to Standard of Care Treatment (Part I)17
SecondaryOptimal Dose Determination With VP Dose Escalation (Part II)

Calculate vascular resistance indicators for CI and CO, and PAPi at each dose level. Identify the VP dose where mPAP, VR(CO), VR(CI), CVP are lowest, and CI/CO are highest. Compare in a narrative to the selected VP optimal dose by the Investigator by individual patient.

Time frame:
Pharmacodynamic changes will be measured during surgery (Day 1), post-surgery (Day 1), and from start of study treatment (Day 1) through study completion (up to 30 days)
Reported as:
Number · ng/kg/min
Optimal Dose Determination With VP Dose Escalation (Part II)
ng/kg/minVentaProst
Optimal VP dose 16.8
Optimal VP dose 210.2
Optimal VP dose 313.6

Adverse events

Collected over Adverse events were collect from post-cardiac surgery (Day 1) through study completion (up to 30 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Epoprostenol Then VentaProst0/7 (0%)1/7 (14.3%)2/7 (28.6%)
Part 2: VentaProst Dose Escalation0/8 (0%)2/8 (25%)1/8 (12.5%)
Most frequent serious events
Most frequent serious events
EventPart 1: Epoprostenol Then VentaProstPart 2: VentaProst Dose Escalation
arterial hemorrhageVascular disorders0/72/8
pulmonary hypertensionCardiac disorders1/70/8
Most frequent other events
Most frequent other events
EventPart 1: Epoprostenol Then VentaProstPart 2: VentaProst Dose Escalation
coagulopathyBlood and lymphatic system disorders1/70/8
adrenal insufficiencyEndocrine disorders1/70/8
acute kidney injuryRenal and urinary disorders1/70/8
acute lung injuryRespiratory, thoracic and mediastinal disorders1/70/8
traumatic hemothoraxRespiratory, thoracic and mediastinal disorders1/70/8
arterial hemorrhageVascular disorders0/71/8
hemorrhageVascular disorders0/71/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1: Epoprostenol Then VentaProstPart 2: VentaProst Dose EscalationTotal
Mean66.0 ± 11.4765.6 ± 8.0265.8 ± 9.41
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Epoprostenol Then VentaProstPart 2: VentaProst Dose EscalationTotal
Female123
Male6612
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Epoprostenol Then VentaProstPart 2: VentaProst Dose EscalationTotal
Hispanic or Latino000
Not Hispanic or Latino7714
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Epoprostenol Then VentaProstPart 2: VentaProst Dose EscalationTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White7613
More than one race011
Unknown or Not Reported000
Weight
Weight(Kg)Part 1: Epoprostenol Then VentaProstPart 2: VentaProst Dose EscalationTotal
Mean85.6 ± 21.1183.6 ± 17.5784.5 ± 18.61
08

Study locations

3 sites
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Mar 2019, 18 months.

Results were first posted in Jul 2025, 6 years 4 months after primary completion.

Of 50 phase 2 interventional studies under Hypertension, Pulmonary, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 71. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2017
First posted
Apr 21, 2017
StartActual
Aug 23, 2017
Primary completionActual
Mar 1, 2019
CompletionActual
May 30, 2019
Results first posted
Jul 31, 2025
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03122730
Lead sponsor
Aerogen Pharma Limited
Responsible party
Sponsor
First posted
Apr 21, 2017
Start date
Aug 23, 2017
Primary completion
Mar 1, 2019
Completion
May 30, 2019
Results posted
Jul 31, 2025
Last update
Jul 31, 2025

Study contacts

Charles Hill, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion